Lv22
198 积分 2021-12-13 加入
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
3天前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
4天前
已完结
Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma
4天前
已完结
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
4天前
已完结
Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma
5天前
已关闭
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
9天前
已完结
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
14天前
已完结
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
14天前
已完结
Frontline Treatment of Mantle Cell Lymphoma
14天前
已完结
A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study
27天前
已完结
皖公网安备34019202002308
